Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company"
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
09:45am, Friday, 21'st Mar 2025
NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such inves
Sarepta: Should Investors Run For The Exit?
01:55pm, Thursday, 20'th Mar 2025
Shares of Sarepta Therapeutics dropped 20% after a patient died from acute liver injury post-ELEVIDYS treatment, an event not previously reported. Despite the tragic news, we believe this is an isolat
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation
10:00am, Thursday, 20'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company"
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?
03:00am, Thursday, 20'th Mar 2025
Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price i
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company"
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
03:15pm, Wednesday, 19'th Mar 2025
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such inves
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
02:40pm, Wednesday, 19'th Mar 2025
Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular dys
Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
06:16pm, Tuesday, 18'th Mar 2025
Investors can contact the law firm at no cost to learn more about recovering their losses
3 Gene Therapy Stocks to Watch Amid Industry Turmoil
03:21pm, Tuesday, 18'th Mar 2025
Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06.
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge
01:30pm, Tuesday, 18'th Mar 2025
U.S. stocks traded lower midway through trading, with the S&P 500 falling around 1% on Tuesday.
Sarepta Therapeutics faces new safety concerns for gene therapy ELEVIDYS following patient death
10:46am, Tuesday, 18'th Mar 2025
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged more than 21% after it revealed a patient with Duchenne muscular dystrophy (DMD) has died following treatment with its gene therapy ELEVIDYS. Alth
Sarepta Therapeutics' stock falls after patient dies of liver failure
09:54am, Tuesday, 18'th Mar 2025
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
09:29am, Tuesday, 18'th Mar 2025
On Tuesday, Sarepta Therapeutics, Inc. SRPT stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne mus
Sarepta says patient dies after treatment with gene therapy
08:17am, Tuesday, 18'th Mar 2025
Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for rare muscular dystrophy.
